Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a dihydrate form of lisinopril, a lysine analogue of MK 421 and a potent, long-acting angiotensin converting enzyme (ACE) inhibitor with an IC50 of 4.7 nM in standard in vitro assays (Tieku & Hooper, 1992). It acts by reducing the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased blood pressure (ApexBio). Lisinopril dihydrate is widely used to model hypertension, heart failure, and nephropathy, with robust documentation supporting experimental reproducibility. The compound is water-soluble (≥2.46 mg/mL with warming/ultrasonication), stable when desiccated at room temperature, and supplied at ≥98% purity with full analytical validation. Its specificity for ACE and compatibility with diverse experimental models make it a reference compound for dissecting renin-angiotensin system dynamics.

Biological Rationale

Lisinopril dihydrate targets the renin-angiotensin system (RAS), a central regulator of vascular tone and fluid balance. ACE (EC 3.4.15.1) converts angiotensin I to the vasoconstrictor peptide angiotensin II, which elevates blood pressure and stimulates aldosterone release. Inhibiting ACE disrupts this pathway, lowering plasma angiotensin II and aldosterone, while increasing renin activity. Lisinopril dihydrate is a lysine-derived ACE inhibitor, structurally related to enalaprilat and MK 421, but distinguished by oral bioavailability and prolonged activity (Tieku & Hooper, 1992). It enables precise experimental modulation of RAS in both acute and chronic disease models, facilitating studies of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (Strategic ACE Inhibition for Next-Gen Models).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate inhibits human ACE with an IC50 of 4.7 nM under standardized in vitro conditions (pH 8.0, 37°C, 50 mM HEPES buffer) (Tieku & Hooper, 1992). It is a non-sulfhydryl, competitive inhibitor that mimics the transition state of the ACE substrate, binding the active site zinc ion. This prevents the cleavage of angiotensin I to angiotensin II. Resultant effects include reduced plasma angiotensin II and aldosterone, increased renin, and decreased systemic vascular resistance. Lisinopril dihydrate exhibits high selectivity for ACE over other zinc metallopeptidases, such as aminopeptidase N (AP-N) and aminopeptidase A (AP-A), minimizing off-target effects (Tieku & Hooper, 1992).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE activity with an IC50 of 4.7 nM (pH 8.0, 37°C), demonstrating high potency in vitro (Tieku & Hooper, 1992).
• It does not significantly inhibit aminopeptidase N (AP-N), AP-A, or AP-W at pharmacologically relevant concentrations, confirming selectivity (Tieku & Hooper, 1992).
• Clinical and preclinical studies show dose-dependent reductions in blood pressure and plasma angiotensin II after lisinopril administration (ApexBio).
• Lisinopril dihydrate is soluble in water at ≥2.46 mg/mL with gentle warming and ultrasonication, but is insoluble in ethanol (ApexBio).
• The compound is supplied at ≥98% purity, confirmed by mass spectrometry and NMR (ApexBio).
• Storage at room temperature in a desiccated environment preserves compound integrity; long-term solutions are not recommended (ApexBio).

Applications, Limits & Misconceptions

Lisinopril dihydrate is a reference compound for modeling hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (Translational Cardiovascular Research). Its mechanism is well suited for studies dissecting the renin-angiotensin pathway, enabling both acute and chronic dosing regimens. Compared to sulfhydryl-containing ACE inhibitors (e.g., captopril), lisinopril offers improved stability and fewer off-target effects (Tieku & Hooper, 1992).

For deeper mechanistic applications, see Unraveling ACE Inhibitor Selectivity, which focuses on ACE isoforms and selectivity. This article extends those discussions by detailing quantitative benchmarks and experimental integration parameters.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase N (AP-N), AP-A, or AP-W at pharmacologically relevant concentrations (Tieku & Hooper, 1992).
• It is not suitable for models requiring non-ACE RAS pathway modulation (e.g., direct angiotensin receptor blockade).
• Lisinopril dihydrate is insoluble in ethanol; aqueous solutions require gentle warming/ultrasonication for full dissolution (ApexBio).
• Long-term storage of reconstituted solutions is discouraged due to potential degradation; always prepare fresh aliquots.
• It is not effective in models that lack functional renin-angiotensin signaling.

Workflow Integration & Parameters

For experimental use, Lisinopril dihydrate (B3290) is provided as a solid (molecular weight 441.52 g/mol, formula C21H35N3O7). Dissolve in water at ≥2.46 mg/mL, using gentle warming (37°C) and ultrasonic treatment if needed. Avoid ethanol. Store powder at room temperature in a desiccator; minimize freeze/thaw cycles. For dosing, standard rodent models typically employ 1–10 mg/kg via oral gavage or drinking water, with plasma angiotensin II and aldosterone as readouts for pathway inhibition. Analytical confirmation (LC-MS, NMR) is recommended for each batch.

For advanced workflows, see Precision ACE Inhibition for Hypertension Models, which provides troubleshooting and protocol adaptation strategies. This article expands on those recommendations with updated solubility and selectivity data.

Conclusion & Outlook

Lisinopril dihydrate is a well-validated, long-acting ACE inhibitor with high selectivity and reproducibility in hypertension and cardiovascular research. Its robust analytical profile, defined solubility, and clear mechanism support its role as a reference standard in RAS pathway studies. Ongoing research is poised to further clarify its applications in precision medicine and disease modeling, with benchmarks and protocols that facilitate rigorous, reproducible science.